However, KMT2A-PTDs are generally associated with a poor prognosis [4,5], and in some studies, with a benefit from hematopoietic stem cell transplantation in first remission [6], reinforcing the need for their identification for the proper clinical management of AML patients. Here, KMT2A is linked to acute myeloid leukemia.